Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study).
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
21
03
2019
revised:
04
07
2019
accepted:
21
08
2019
pubmed:
11
9
2019
medline:
6
10
2020
entrez:
11
9
2019
Statut:
ppublish
Résumé
HCV-RNA assessment during therapy with Direct-Acting Antiviral (DAA) regimens still relies on assays requiring blood collection and transport to a specialised laboratory, which may compromise linkage to care. GeneXpert-HCV Viral Load (GXHVL) (Cepheid) is a plasma-based assay used at point of care (POC) with a sensitivity of ≤10 IU/mL, and, results available within 2 hours. Fifty-nine consecutive HCV-patients ready for DAAs treatment were enrolled. HCV-RNA was simultaneously tested using Roche TaqMan RT-PCR (venous blood sample) and GXHVL (capillary blood collected by fingerstick), at baseline (BL), week 4 (W4) of therapy, end of therapy (EOT) and week 12 of follow-up (W12FU). Both assays demonstrated undetectable HCV-RNA in all patients at EOT and identified the single case of HCV-relapse at W12FU. GXHVL used as a point-of-care assay in the outpatient setting provides results fully comparable to the laboratory-based test. Its excellent performance and ease of use suggest its adoption in non-specialist settings where simplicity of care is paramount to implement HCV eradication campaigns.
Substances chimiques
Antiviral Agents
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2240-2243Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct-acting agent therapy for Hepatitis C Virus infection: a systematic review. Ann Intern Med. 2017;166(9):637-648.
Liu CH, Huang YJ, Yang S, et al. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep. 2018;8(1):13699.
European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511.
World Health Organization. Global health sector strategy on viral hepatitis, 2016-2021. 2016. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. Accessed June, 2016.
Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45-S57.
Calvaruso V, Petta S, Craxì A. Is global elimination of HCV realistic? Liver International. 2018;38(Suppl 1):40-46.
Tucker JD, Bien CH, Peeling RW. Point-of-care testing for sexually transmitted infections: recent advances and implications for disease control. Curr Opin Infect Dis. 2013;26:73-79.
Grebely J, Lamoury F, Hajarizadeh B, et al. Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. Lancet Gastroenterol Hepatol. 2017;2(7):514-520.
European Association for the Study of the Liver. EASL recommendations on treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153-194.
World Health Organisation. WHO guidelines on drawing blood: Best practices in phlebotomy. 2010. http://www.ncbi.nlm.nih.gov/books/NBK138654/
Llibre A, Shimakawa Y, Mottez E, et al. Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut. 2018;67(11):2017-2024.
Lamoury F, Bajis S, Hajarizadeh B, et al. Evaluation of the Xpert HCV viral load finger-stick point-of-care assay. J Infect Dis. 2018;217(12):1889-1896.